To assess the impact of minimal residual disease (MRD) and tyrosine kinase inhibitor (TKI) administration on allogeneic hematopoietic cell transplantation (allo-HCT) for Ph-positive ALL (Ph+ALL), we retrospectively analyzed data from a registry database for 432 adult Ph+ALL patients in first CR (CR1) who received pre-transplant TKI administration. Negative MRD (MRD(− )) at allo-HCT was achieved in 277 patients. OS in patients transplanted in MRD( − ) was significantly better than that in patients transplanted in MRD(+) (MRD( − ): 67% vs MRD(+): 55% at 4 years; P = 0.001). MRD( − ) at allo-HCT was a significant risk factor for survival along with age at allo-HCT in multivariate analyses. Incidence of relapse in patients transplanted in MRD( − ) was significantly lower than that in patients transplanted in MRD(+) (MRD( − ): 19% vs MRD(+): 29% at 4 years; P = 0.006). In multivariate analyses, MRD(+) at allo-HCT was a significant risk factor for relapse. A post-transplant TKI was administered to 103 patients. In subanalyses regarding the effect of post-transplant TKI administration, post-transplant TKI administration was a significant risk factor for relapse in multivariate analyses (P o0.0001). MRD status at allo-HCT is one of the most important predictive factors for Ph +ALL patients transplanted in CR1.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is still considered to be a choice to cure in Ph-positive ALL (Ph+ALL). [1] [2] [3] [4] [5] Since hematological CR can be achieved in many patients in the era of tyrosine kinase inhibitors (TKIs), 6, 7 monitoring minimal residual disease (MRD) is important for long-term disease control. [8] [9] [10] [11] [12] Therefore, increasing attention has been paid to MRD status at allo-HCT. 13, 14 Post-transplant TKI administration is another issue that has received increasing attention, 13, 15, 16 since relapse after allo-HCT is still one of the main problems of this disease. 1, 16 Although there have been several small-scale studies on post-transplant TKI administration, [17] [18] [19] the utility of post-transplant TKI administration for long-term survival of Ph+ALL patients is controversial.
In this study, we analyzed the impact of MRD status at allo-HCT on the outcome of allo-HCT for Ph+ALL patients to determine the appropriate timing of allo-HCT. We also assessed the utility of post-transplant TKI administration to evaluate the impact of post-transplant intervention on long-term survival.
PATIENTS AND METHODS

Collection of data and data source
Recipients' clinical data were provided by the Japan Society for Hematopoietic Cell Transplantation (JSHCT), which collected recipients' clinical data at 100 days after allo-HCT. Data on survival, disease status and long-term complications, including chronic GVHD and secondary malignancies, are renewed annually by follow-up forms. This study was approved by the data management committees of JSHCT as a study of the adult ALL Working Group of JSHCT. Informed consent was obtained from both recipients and donors in accordance with the Declaration of Helsinki.
Patients
Data for 918 patients of at least 16 years of age who underwent their first allo-HCT for Ph+ALL in CR1 between 1990 and 2010 were available in the registration database of JSHCT. As clinical trial in Japan, 60 patients received allo-HCT in CR1 in the JALSG Ph+ALL202 study (registered between September 2002 and May 2005) 20 and 43 patients received allo-HCT in CR in the Japan Adult Leukemia Study Group (JALSG) Ph+ALL208IMA study (registered between October 2008 and December 2010). 21 Additional data for the use of pre-and post-transplant TKI administration and MRD at and after allo-HCT were collected for this study. A pre-transplant TKI was administered in 592 of the 918 patients. After excluding 160 patients for whom data on MRD status at allo-HCT were missing, we analyzed data for 432 adult Ph+ALL patients who underwent allo-HCT between 2002 and 2010. Only BM grafts were used in unrelated allo-HCT because peripheral blood stem cell donation from unrelated donors was approved in 2010 in Japan.
Definitions
Ph+ALL was diagnosed by the presence of Ph through chromosome and/ or FISH analysis and by positivity for BCR-ABL fusion transcript detection by RQ-PCR analysis. The timing and procedure of allo-HCT, including conditioning regimen, GVHD prophylaxis and assessment for BCR-ABL fusion transcripts were determined by each institution. In this study, data for BCR-ABL fusion transcripts were collected retrospectively. In most laboratories, the copy numbers of BCR-ABL transcripts were converted to molecules per microgram of RNA after being normalized by means of GAPDH. The normalized values of the BCR-ABL copies in each sample were reported as the BCR-ABL copy number. The threshold for quantification was 50 copies per μg RNA, which corresponded to a minimal sensitivity of 10
. 2 In the present study, 'not detected' by RQ-PCR was defined as negative MRD ((MRD(− )). MRD at the time of allo-HCT was evaluated by the results of RQ-PCR within 30 days prior to respective transplantation. Determination of whether to prescribe a TKI after allo-HCT was also made by each institution.
Neutrophil recovery was defined by an absolute neutrophil count of at least 0.5 ×10 9 /L for 3 consecutive days, and platelet recovery was defined by a count of at least 50 × 10 9 /L without transfusion support. Acute GVHD and chronic GVHD were diagnosed and graded according to consensus criteria. 22, 23 Relapse was defined as hematologic leukemia recurrence. Non-relapse mortality (NRM) was defined as death during continuous remission. For analyses of OS, failure was death from any cause, and surviving patients were censored at the date of last contact. We defined a reduced-intensity regimen as having the following dosage levels: busulfano 9 mg/kg, melphalan ⩽ 140 mg/m 2 and TBIo 500 cGy (single) or 500-800 cGy (fractionated). 24 HLA matching of cord blood (CB) was performed using low-resolution typing for HLA-A, -B and -C, and highresolution molecular typing for HLA-DRB1. HLA matching of unrelated donors was performed using high-resolution typing for HLA-A, -B, -C and HLA-DRB1. [25] [26] [27] For related and unrelated donors, 'well-matched' was defined as no known disparity at HLA-A, -B, -C or -DRB1, 'partially matched' was defined as one locus disparity with their donors and 'mismatched' was defined as two or more locus disparities. For CB, 'well-matched' was defined as no known disparity at HLA-A, -B, -C or -DRB1, 'partially matched' was defined as at least four-locus matches and 'mismatched' was defined as three or less locus matches since CB of at least 4/6 HLA-matched and total nucleated cells ⩾ 2 × 10 7 /kg or CD34 + cells ⩾ 1 × 10 5 /kg are preferentially selected in Japan. 13, [28] [29] [30] 
Statistical analysis
The primary end point of this study was OS after allo-HCT. Secondary end points included leukemia-free survival (LFS), incidence of relapse and NRM. OS rates were estimated by the Kaplan-Meier method and P-values were calculated using a log-rank test. 31, 32 Cumulative incidences of relapse, NRM and GVHD were calculated by Gray's method. 33, 34 Death without relapse was considered as a competing event for relapse, and relapse was considered as a competing event for NRM. Univariate and multivariate analyses were performed using a Cox proportional hazard regression model for survival, 35 and a Fine-Gray proportional hazard regression model for relapse and NRM. 36 A significance level of Po0.05 was used for all analysis. Covariates included in the multivariate analyses were age at allo-HCT, HLA disparity, additional chromosomal abnormality, MRD status at allo-HCT (MRD(− ) vs MRD(+)), conditioning regimens, year of allo-HCT, interval from diagnosis to allo-HCT, donor source and GVHD prophylaxis.
RESULTS
Patient characteristics
The characteristics of the patients are shown in Table 1 . Of the 432 patients, 277 received allo-HCT in MRD( − ) and 155 received allo-HCT in MRD(+). In Japan, imatinib was available for Ph+ALL primarily in a clinical study of JALSG Ph+ALL202 and has been widely used since 2005. Of 425 patients with data for post-transplant TKI administration, 103 patients received posttransplant TKI.
Survival
The median follow-up period for survivors was 48 months (range 2.2-125 months). OS rates at 4 years were 67% in MRD( − ) and 55% in MRD(+) (P = 0.001; Figure 1a) . Results of multivariate Abbreviations: allo-HCT = allogeneic hematopoietic cell transplantation; CB = cord blood; MAC = myeloablative conditioning; MRD = minimal residual disease; PB = peripheral blood; RIC = reduced-intensity conditioning; y = years.
Impact of MRD and TKI on allo-HCT for Ph+ALL S Nishiwaki et al analysis showed that age and MRD status at allo-HCT were significant risk factors for OS (Table 2) . LFS rates at 4 years were 60% in MRD( − ) and 46% in MRD(+) (P = 0.0004; Figure 1b) . Results of multivariate analysis showed that age and MRD status at allo-HCT were significant risk factors for LFS (Table 2 ).
In subanalyses of 324 patients under the age of 55 treated with a myeloablative conditioning regimen, OS was significantly lower in patients who underwent allo-HCT in MRD(+) than those who underwent allo-HCT in MRD( − ) (72% in MRD( − ) vs 58% in MRD(+) at 4 years; P = 0.002). Similarly, LFS was significantly lower in patients who underwent allo-HCT in MRD(+) than those who underwent allo-HCT in MRD( − ) (65% in MRD( − ) vs 48% in MRD(+) at 4 years; P = 0.0002). TBI regimen was used for 310 patients. Non-TBI regimen was not a significant risk factor for OS and LFS in a Cox model (OS: hazard ratio (HR) 1.30, 95% confidence interval (CI) 0.65-2.57, P = 0.46; LFS: HR 1.42, 95% CI 0.79-2.57, P = 0.25).
Relapse and NRM The cumulative incidence of relapse was significantly lower in patients who underwent allo-HCT in MRD( − ) than in those who underwent allo-HCT in MRD(+) (19% in MRD( − ) and 29% in MRD (+) at 4 years, P = 0.006; Figure 1c) . Results of multivariate analysis showed that MRD(+) at allo-HCT was a significant risk factor for relapse ( Table 2) .
The cumulative incidence of NRM was not significantly different between patients who underwent allo-HCT in MRD( − ) and those who underwent allo-HCT in MRD(+) (21% in MRD( − ) and 25% in MRD(+) at 4 years, P = 0.12; Figure 1d) . Results of multivariate analysis showed that age and HLA disparity were significant risk factors for NRM (Table 2 ).
In subanalyses of 324 patients under the age of 55 treated with a myeloablative conditioning regimen, the cumulative incidence of relapse was significantly lower in patients who underwent allo-HCT in MRD( − ) than those who underwent allo-HCT in MRD(+) (19% in MRD( − ) vs 31% in MRD(+) at 4 years; P = 0.003). The cumulative incidence of NRM was not significantly different between patients who underwent allo-HCT in MRD( − ) and those who underwent allo-HCT in MRD(+) (17% in MRD( − ) vs 21% in MRD(+) at 4 years; P = 0.14). Non-TBI regimen was not a significant risk factor for relapse and NRM in a Fine-Gray model (relapse: HR 1.18, 95% CI 0.51-2.72, P = 0.69; NRM: HR 1.51, 95% CI 0.64-3.52, P = 0.34).
Causes of death Of 164 deaths after allo-HCT, the most common cause was relapse (41%). Infection (20%), organ failure (11%) and GVHD (7%) were the major three causes of NRM, and the sum of these three incidences was approximately equivalent to the incidence of death from relapse (Table 3) .
Other outcomes of allo-HCT The cumulative incidence of neutrophil recovery or platelet recovery was significantly lower in patients who underwent CB Impact of MRD and TKI on allo-HCT for Ph+ALL S Nishiwaki et al allo-HCT (neutrophil recovery: 98% in BM, 97% in peripheral blood and 81% in CB at day 100, P o0.0001; platelet recovery: 87% in BM, 94% in peripheral blood and 68% in CB at 1 year, P o 0.0001).
The cumulative incidence of grade III-IV acute GVHD was not significantly different between patients who underwent allo-HCT in MRD( − ) and those who underwent allo-HCT in MRD(+) (7% in MRD( − ) and 9% in MRD(+), P = 0.39).
Among evaluable patients who survived at least 100 days after allo-HCT, no significant difference was observed in the incidence of chronic GVHD between patients who underwent allo-HCT in MRD( − ) and those who underwent allo-HCT in MRD(+) (32% in MRD( − ) and 33% in MRD(+), P = 0.59).
Post-transplant TKI administration
The median day of post-transplant TKI administration was day 141 (range days . Imatinib was administered to 85 patients (83%; median dose: 400 mg per day) and dasatinib was administered to 18 patients (17%; median dose: 100 mg per day). Post-transplant TKI was administered to 34 patients Abbreviations: allo-HCT = allogeneic hematopoietic cell transplantation; CB = cord blood; CI = confidence interval; HR = hazard ratio; MAC = myeloablative conditioning; MRD = minimal residual disease; PB = peripheral blood; RIC = reduced-intensity conditioning; y = years.
without molecular relapse (prophylactic), to 24 patients with molecular relapse (preemptive), to 42 patients with hematological relapse and to 3 patients with unknown timing. In multivariate analyses including presence or absence of prophylactic or preemptive post-transplant TKI administration as a timedependent covariate (excluding post-transplant TKI administration for patients with hematological relapse), post-transplant TKI administration was a significant risk factor for LFS and relapse (Table 4 ). In subanalyses of 324 patients under the age of 55 treated with a myeloablative conditioning regimen, posttransplant TKI administration was a significant risk factor for LFS and relapse along with MRD(+) at allo-HCT (LFS: HR 1.97, 95% CI 1.22-3.18, P = 0.005; relapse: HR 17.7, 95% CI 9.95-31.4, Po 0.0001).
Results of univariate analyses showed that post-transplant TKI administration was a significant risk factor for LFS in patients transplanted in MRD( − ) (HR 2.10, 95% CI 1.21-3.64, P = 0.008) and a borderline risk factor for LFS in patients transplanted in MRD(+) (HR 1.77, 95% CI 0.98-3.20, P = 0.06).
Post-transplant MRD data were available for 388 patients. The median day of the post-transplant MRD test was day 61 (range days 13-1762), and molecular relapse was observed in 44 patients. In subanalysis comparing survival of 7 patients who were not administered a TKI at molecular relapse and that of 24 patients who received preemptive TKI administration, preemptive administration was not associated with superior OS (P = 0.87).
DISCUSSION
This study provided results of the largest series of analyses concerning MRD and TKI administration among Ph+ALL patients transplanted in CR1. MRD( − ) at allo-HCT was strongly associated with better survival after allo-HCT. Since the interval from diagnosis to allo-HCT was not a significant prognostic factor, reduction of MRD to 'not detected' level before allo-HCT would be important after achieving hematological remission.
Deciding the timing of allo-HCT for Ph+ALL patients might have a direct benefit for the clinical situation. Considering that second and third generation TKIs have recently become available, [37] [38] [39] [40] [41] patients with MRD who have been treated with imatinib could have a chance to achieve molecular CR before allo-HCT. Our results suggested that it would be better for patients with MRD to undergo additional therapy to reduce MRD than to undergo immediate allo-HCT.
Imatinib-based therapy has increased the proportion of patients who achieve sustained remission, thus providing additional time for suitable donor selection and enabling individualized treatment approaches. 2, 3 These secondary benefits may have contributed to the lower NRM in patients who received pre-transplant imatinib administration.
Surprisingly, post-transplant TKI administration was suggested to be a significant adverse prognostic factor for relapse. Our previous small-scale study suggested the limitation of post-transplant imatinib administration: OS was significantly better in patients with post-transplant administration, but there was no significant difference in LFS, 13 being compatible with the results of this study. As for NRM, it might be underestimated in patients with posttransplant administration because of technical issues of competing risk analyses: of 103 patients with post-transplant administration, NRM was observed in only 3 patients (3%) whereas relapse was observed in 71 patients (69%). Since the decision to prescribe a TKI after allo-HCT was made by each institution in this study, the TKI might have been administered to patients who were potentially at Abbreviations: ARDS = acute respiratory distress syndrome; SOS = sinusoidal obstruction syndrome; TMA = thrombotic microangiopathy.
a Extramedullary relapse was observed in eight patients: central nervous system in four, lymph node in one, liver in one and other/unknown in two patients. Five patients died of acute GVHD and six died of chronic GVHD. Abbreviations: allo-HCT = allogeneic hematopoietic cell transplantation; CI = confidence interval; HR = hazard ratio; MRD = minimal residual disease; TKI = tyrosine kinase inhibitor; y = years.
Impact of MRD and TKI on allo-HCT for Ph+ALL S Nishiwaki et al high risk for relapse. Although post-transplant TKI administration could not prevent relapse in such patients, prolonged OS may be beneficial at the present time with the possibility that an innovative new drug will be developed in the near future.
To minimize the effect of latent difference of background, we performed two subgroup analyses: analysis for patients with MRD + at allo-HCT and analysis for patients with molecular relapse after allo-HCT. Post-transplant TKI administration was not associated with significantly better survival in either of the subanalyses, being consistent with the results of a previous study. 42 Limitation of post-transplant TKI administration suggested a need for additional strategies to improve the outcome of patients whose MRD is positive at or after allo-HCT.
The post-transplant TKI was imatinib in most of the patients (83%) in this study. Since selection of the TKI depended on the individual institution, it was difficult to assess the differences in TKIs. Recently, there have been several small-scale studies indicating the utility of post-transplant dasatinib. 17, 18 Although further studies are needed to confirm the utility, different effects of different TKIs deserve consideration.
Timing of MRD detection may be another issue. In a past study, early molecular response to post-transplant TKI administration was associated with prolonged LFS, although continued detection of MRD after allo-HCT would lead to hematological relapse. 43 Since MRD was checked according to the policy of the individual institution in this retrospective study, the results of a prospective study in which the timing of MRD tests is defined in the study protocol should resolve this issue.
In conclusion, MRD( − ) at allo-HCT was one of the most influential prognostic factors for Ph+ALL patients transplanted in CR1. Sufficient pre-transplant chemotherapy combined with a pretransplant TKI(s) can lead to long-term survival after allo-HCT. In addition, limitation of retrospective analyses for post-transplant TKI administration was indicated in this study. Although prospective analysis is needed to confirm the utility of post-transplant TKI administration, an MRD-based strategy is necessary to determine the appropriate timing of allo-HCT in the era of TKIs.
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